News · United States · 2026-06-17
FTC and four states sue WPATH over deceptive claims about pediatric medical transition
The Federal Trade Commission, joined by Alaska, Iowa, Nebraska and Texas, has filed a federal complaint against the World Professional Association for Transgender Health. The allegation: WPATH's Standards of Care misled parents about the necessity, safety and effectiveness of puberty blockers, cross-sex hormones and surgery in minors.
Core
The FTC alleges that WPATH, an association of clinicians who profit from pediatric medical transition services, provided the means by which providers made false and unsubstantiated claims to parents in violation of the FTC Act. The Commission vote authorizing the filing was 2-0. The complaint was filed in the U.S. District Court for the Northern District of Texas.
The four core allegations
The complaint, filed on 17 June 2026, rests on four factual allegations against WPATH. Each stands on its own; together they form a pattern that, in the FTC's view, amounts to consumer deception.
1. Removing age limits in SOC8 (2022)
In 2022, WPATH omitted all mention of age limitations for breast amputation or penis removal from its Standards of Care. As alleged in the complaint, WPATH did not base this decision on medical evidence.
2. Failure to disclose side effects
The complaint enumerates side effects that WPATH allegedly failed to disclose to parents and patients. Cross-sex hormones can cause mood disturbances, vocal pain and limitations, pelvic pain, clitoral discomfort, vaginal pain, inability to orgasm, incontinence and erectile pain. These side effects are listed in the complaint as risks that, according to the FTC, WPATH failed to disclose.
3. The "lifesaving" frame without evidence
In several instances, the complaint describes, parents seeking help for their children were asked by clinicians whether they "would rather have a live daughter or a dead son." That framing relies on WPATH's representation that pediatric medical transition services are "lifesaving." As the complaint argues, there is no competent and reliable scientific evidence that these interventions reduce the risk of suicide. The Cass Review likewise writes that the evidence does not sufficiently support the claim that gender-affirming treatment lowers the risk of suicide (source).
4. "Medically necessary" as an insurance lever
WPATH presents its recommendations as "consensus-based expert opinion" and labels nearly every pediatric transition service as "medically necessary." According to the complaint, that label is not supported by competent and reliable scientific evidence and was used to maximise the likelihood that insurers pay for the procedures.
Why this matters for the Dutch track
The Dutch Kwaliteitsstandaard Transgenderzorg states that it aligns with the WPATH Standards of Care (version 7, 2012) and the Endocrine Society guideline (2017) (source). The Dutch Protocol was developed in the Netherlands and later adopted internationally (source); the Dutch standard is being revised after the minister's 2024 evaluation found it no longer entirely up to date in places (source).
An American federal complaint concerns claims about the Standards of Care that the Dutch standard also cites. The allegations are those of the FTC and the four states.
Continue in this dossier
Physician liability
What the "I followed the guideline" defense means once the guideline itself is alleged to mislead.
WPATH Files (2024)
Leaked internal WPATH messages, published by Environmental Progress, which draws its own conclusions from them.
Cass Review (2024)
The 388-page report, commissioned by NHS England, that calls research on care for young people with gender dysphoria an area of remarkably weak evidence.
Source
Federal Trade Commission, press release 17 June 2026: FTC, States Sue World Professional Association for Transgender Health Over Deceptive Claims Regarding the Treatment of Children. ftc.gov